Digital Genome Market Size By Product (Sequencing & Analyzer Instruments, DNA/RNA Analysis Kits, Sequencing Chips, Sequencing & Analysis Software, Sample Preparation Instruments), By Application (Microbiology {Biological, Clinical, Industrial}, Reproductive & Genetic, Transplantation, Livestock and Agriculture, Forensics, Research and Development), By End-Use (Diagnostics & Forensic Labs, Academi

Digital Genome Market Size By Product (Sequencing & Analyzer Instruments, DNA/RNA Analysis Kits, Sequencing Chips, Sequencing & Analysis Software, Sample Preparation Instruments), By Application (Microbiology {Biological, Clinical, Industrial}, Reproductive & Genetic, Transplantation, Livestock and Agriculture, Forensics, Research and Development), By End-Use (Diagnostics & Forensic Labs, Academi

Digital Genome Market Size

Digital Genome Market size crossed $26 billion in 2018 and is projected to register over 10% CAGR up to 2025.
 

Digital genome is a comprehensive digital set of genetic material that occurs in a cell or an organism. It is a simpler way to gather information concerning chronic diseases and utilized by experts to get a nearer look of genetic disorders. A digital genome acts as a supporter that facilitates instant access to trait sequences to resolve unending custom queries. Thus, aforementioned parameters will augment the market growth. Digital genomics deals with genes & their functions and assists in finding causes behind chronic disorders and also to resolve them. This technology has sparked a revolt in invention-centred research & systems biology to expedite insight of the most complex genetic systems.
 

Genome market can be traced back to late 1926 when the term genomics was invented by Tom Roderick, a geneticist at the Jackson Laboratory. The 1^st complete genome sequence of the human mitochondrion (16.6 kb), was registered in 1981. Also, with accomplishment of the Human Genome Project in 2003, every single human gene sequences were accessible in the public domain. Furthermore, in 2012, a modern technique named CRISPR has transformed genome editing, by making it much easier, cheaper, swifter & more precise than former methods. Digital genomics is swiftly advancing field in medical research and is estimated to transmute the healthcare approach in the near future. It enabled determination of individual distinctive genetic make-up at a very high speed and affordable price that have bought a revolution in healthcare sector.
 

The industry will witness an influx of new and private players offering innovative and affordable coverage in future. Also, industry players are investing immensely in R&D processes to offer distinguished solutions and gain competitive advantage. Furthermore, various government organizations are putting efforts to streamline volunteering process in the genomics-based clinical trials. Developed countries are implementing genome-based technologies in numerous areas of healthcare.
 

Digital Genome Market Trends

The digital genome market is expected to grow at a significant pace in forthcoming years, owing to escalating usage of precision medicines ought to provide profitable growth prospects for this market. The soaring application of digital genomics in next generation sequencing and extensive use of microorganisms in diagnostics industry will further boost the growth. Moreover, escalating number of private and public funds are predicted to push the market expansion over the forecast years.
 

Biotechnology invention has led to production, advancement and commercialization of genetically modified organisms (GMOs). These organisms have extensive applications in clinical diagnosis and research that will contribute to industry growth. In addition, biotechnology firms are replacing traditional methods of gene sequencing in plants by novel techniques. For instance, development of Bt cotton by introduction of the Bt gene from Baccilus thuringenesis is used for providing resistance against pests. The advancement has created a positive impact in digital genomics industry. Nonetheless, aspects such as lack of awareness regarding digital genome, security & privacy of patient data, and incorrect results are likely to obstruct the market expansion during the projected period.
 

Digital Genome Market Analysis

The digital genome market by product is segmented into sequencing & analyzer instruments, DNA/RNA analysis kits, sequencing chips, sequencing & analysis software and sample preparation instruments segment. The sequencing & analyzer software segment accounted for over 12% of the market share in 2018. Technological upgrades in software packages for fabrication and evaluation of genomic sequence data will drive segmental progress. Also, a large amount of software tools that are in the developmental stage will positively impact the global market expansion over the forecast timeframe. Thus, increasing venture capital and grant for biotech research will propel sequencing & analyzer software demand over the coming years.
 

Based on application, digital genome market is sectored into microbiology, reproductive & genetic, transplantation, livestock and agriculture, forensics and research and development. The microbiology segment is further segregated into biological, clinical and industrial segments. Research and development led digital genome market will surpass USD 25 billion by 2025. Growing number of public and private investments and surge in research grants should drive industry expansion. For instance, National institute of Health (NIH) is the is the prominent public fund provider, spending around USD 40 billion per year for ongoing biomedical research for Americans. NIH funded research has led to breakthroughs such as using next-generation DNA sequencing to map landscape of the cancer genome & discover new changes linked to disease. This innovation led to growth of digital genome industry.
 

On the basis of end-use, digital genomics segmented into diagnostics & forensic labs, academic research institutes, hospitals and bio-pharmaceutical companies. Academic research institutes accounted for significant revenue share in digital genome market in 2018. This segment is experiencing high growth owing to widespread application of genome sequencing techniques for advancement of targeted drug treatments. For instance, National Human Genome Research Institute (NHGRI) collaborates with the National Institute of Cancer (NIC), to enhance genomic advances through the initiatives such as Cancer Genome Characterization Initiative (CGCI) & The Cancer Genome Atlas (TCGA). NHGRI has designed Clinical Genomic Database (CGD) of disease conditions with known genetic causes, aiming on pathologically substantial genetic data with accessible interventions.
 

Europe digital genome industry was valued over USD 6.8 billion in 2018 and is estimated to exhibit healthy growth owing to presence of numerous market players racing to seize maximum business share. In Europe, Russia digital genomics is estimated to expand at 11.4% CAGR from 2019 to 2025. The development of “Genome Russia” project is a classic example of Russia’s contribution to progression of digital genome market. The main aim of this project was to create an open access web-based database of medically relevant genomic variants characteristic to Russian population (about 3000 men & women).It also helped to identify the features that affect proliferation of diseases that would eventually lead to development of future personalized medication.
 

The U.S. digital genomics is anticipated to register significant growth during projected period. The well-established healthcare infrastructure, discovery of new genome sequencing technologies and increasing geriatric population will contribute towards revenue growth. Constant innovation, high-end technology, acquisitions and novel product launches in the U.S. has positively impacted the overall market growth. For instance, in 2017, Becton, Dickinson and Company, proclaimed the launch of BD Rhapsody, specifically designed for single cell analysis with the capacity to detect rare molecules accountable for genetic diversity that is frequently lost through whole transcriptome profiling. This launch helped to lower testing time and reduce gene sequencing prices.
 

Digital Genome Market Share

F. Hoffmann-La Roche Ltd. is one of the leaders in biotechnology, in-vitro diagnostics and tissue-based cancer diagnostics. The company is operating in the industry since 1896 and undertakes various strategic initiatives including new product launch to strengthen its business. Other key players operating in global industry include

• Agilent Technologies
• Becton Dickinson
• Pacific Biosciences
• Perkin Elmer
• Thermo Fisher

These companies adopt various policies such as acquisitions, mergers, geographic expansion, to expand business.

Recent industry developments

• In October 2019, Inscripta, one of the leading digital genome engineering firm, has launched Onyx, a digital genome engineering platform, the 1st fully automated benchtop device for genome-level work. The new genome platform will provide instantaneous and key benefits that will assist healthcare, genome discovery.
   
• In March 2018, - Exactis Innovation, an NGO dedicated to drive precision cancer research & access to targeted therapies, stated that the program's NGS-based findings will be regulated utilizing Thermo Fisher Scientific's Ion GeneStudio S5 Series & Oncomine assays systems. This initiative will aid the cancer patients across Canada to have their tumors genetically profiled using next generation sequencing.
   

The digital genome market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2014 to 2025, for the following segments

Click here to Buy Section of this Report

By Product

• Sequencing & analyzer instruments
• DNA/RNA analysis kits
• Sequencing chips
• Sequencing & analysis software
• Sample preparation instruments

By application

• Microbiology
  • Biological
  • Clinical
  • Industrial
• Reproductive & Genetic
• Transplantation
• Livestock and Agriculture
• Forensics
• Research and Development

By end-use

• Academic Research Institutes
• Diagnostics & Forensic Labs
• Hospitals
• Bio-pharmaceutical Companies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia